Efficient intraocular penetration of topical anti-TNF-α single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 2, 2009, Pages 779-786

  Ottiger, Michael ^a   Thiel, Michael A ^b   Feige, Ulrich ^a   Lichtlen, Peter ^a   Urech, David M ^a  

^a ESBATech AG   (Switzerland)

^b Luzerner Kantonsspital ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ESBA 105; PENETRATION ENHANCING AGENT; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; EYE DROPS; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN FV; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR EYE SEGMENT; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORNEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; EXPERIMENTAL RABBIT; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RETINA; TIME TO MAXIMUM PLASMA CONCENTRATION; VITREOUS BODY; ABSORPTION; ANIMAL; BIOAVAILABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HALF LIFE TIME; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; METABOLISM; RABBIT; TISSUE DISTRIBUTION; TOPICAL DRUG ADMINISTRATION;

ABSORPTION; ADMINISTRATION, TOPICAL; ANIMALS; ANTERIOR EYE SEGMENT; ANTIBODIES, MONOCLONAL; AQUEOUS HUMOR; BIOLOGICAL AVAILABILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALF-LIFE; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; MALE; OPHTHALMIC SOLUTIONS; RABBITS; RETINA; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA; VITREOUS BODY;

EID: 59449107918     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2372     Document Type: Article

References (14)

1. Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina. 2007; 27(4):399-413.
2. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007;18(6):502-508.
3. Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol. 2007;144(4):627- 637.
4. Kourlas H, Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther. 2007; 29(9):1850-1861.
5. Thiel MA, Coster DJ, Standfield SD, et al. Penetration of engineered antibody fragments into the eye. Clin Exp Immunol. 2002;128(1): 67-74.
6. Williams KA, Brereton HM, Farrall A, et al. Topically applied antibody fragments penetrate into the back of the rabbit eye. Eye. 2005;19(8):910 -913.
7. Burstein NL. Preservative alteration of corneal permeability in humans and rabbits. Invest Ophthalmol Vis Sci. 1984;25(12): 1453-1457.
8. Furrer P, Mayer JM, Plazonnet B, Gurny R. Ocular tolerance of absorption enhancers in ophthalmic preparations. AAPS Pharm-Sci. 2002;4(1):E2.
9. Auf der Maur A, Escher D, Barberis A. Antigen-independent selection of stable intracellular single-chain antibodies. FEBS Letters. 2001;508(3):407- 412.
10. Furrer E, Berdugo M, Stella C, et al. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-α singlechain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci. 2008;50:771-778.
11. Brereton HM, Taylor SD, Farrall A, et al. Influence of format on in vitro penetration of antibody fragments through porcine cornea. Br J Ophthalmol. 2005;89(9):1205-1209.
12. Kim JH, Green K, Martinez M, Paton D. Solute permeability of the corneal endothelium and Descemet's membrane. Exp Eye Res. 1971;12(3):231-238.
13. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46(2):726 -733.
14. Perez-Guijo V, Santos-Locomba M, Sanchez-Hernandez M, et al. Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin. 2004;20(2):155-157.